Exploring the Global Market for Varicella Zoster Vaccines Market: Demand, Distribution, and Access



Varicella-zoster virus causes two distinct infections, primary varicella (chickenpox) and herpes zoster (shingles). The virus remains dormant in the dorsal root ganglia and cranial nerve ganglia after primary infection. It can reactivate decades later to cause herpes zoster. Vaccination against varicella-zoster virus helps reduce the risk of both chickenpox and shingles. The varicella vaccine contains a live, weakened form of Varicella Zoster HHV-3 Infections virus. It provides long-lasting protection against chickenpox. The shingles vaccine contains a highly purified Varicella Zoster HHV-3 Infections Market to help reduce the risk of developing shingles.

The Global Varicella Zoster (HHV-3) Infections Market is estimated to be valued at USD 1.79 billion in 2024 and is expected to reach USD 2.52 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2031. 

Key Takeaways

Key players operating in the varicella zoster HHV-3 infections market are GlaxoSmithKline plc, Merck & Co. Inc., Sanofi Pasteur, and Seqirus.

Growing demand for varicella and herpes zoster vaccines will open up opportunities in emerging markets. Advancements in vaccine formulations promising longer durability and improved efficacy will further support market growth.

Technological advancement in vaccine development includes the availability of recombinant zoster vaccine that provides stronger and longer-lasting protection against shingles. This new vaccine uses recombinant DNA technology while older ones used whole virus.

Market Drivers

Rising cases of chickenpox and shingles globally due to an aging population are driving the need for preventive immunization. As immunity decreases with age, the risk of reactivation of the varicella-zoster virus increases, leading to herpes zoster. Growing awareness about the availability of effective prevention options through vaccination programs will further augment the market expansion.

Current Challenges in Varicella Zoster HHV-3 Infections Market
The varicella zoster virus remains persistent in the body even after the initial infection is controlled. This virus can reactivate later in life to cause shingles. The incidence of shingles is rising due to aging populations and those with compromised immune systems are more vulnerable. Another key challenge is increasing antidrug resistance as treatments and prophylactic vaccines have been in use for decades. Younger populations also remain at risk as vaccine coverage is not universal. Addressing these challenges through new vaccine formulations and antiviral drugs will be important to control outbreaks and reduce the disease burden.

SWOT Analysis
Strength: Existing vaccines provide protection against initial infection and reduce occurrence of shingles. However, vaccine efficacy wanes over time.                                                        Weakness: Virus reactivation leads to shingles which causes severe pain. No vaccine provides lifetime protection against reactivation.                                                                        Opportunity: Higher risk groups can be targeted for preventive vaccination programs. Large untapped markets remain in developing nations.                                                                   Threats: Emergence of drug resistant strains can undermine existing treatment protocols. Rising healthcare costs associated with the disease pose challenges.

In terms of value, the United States and major Western European markets account for over 60% of the current varicella zoster virus market due to higher per capita healthcare spending and vaccine uptake in these regions. The Asia Pacific region is projected to grow at the fastest pace during the forecast period. Countries like China and India have large susceptible populations but vaccine penetration is relatively low currently due to financial constraints in public health programs. However, rising incomes are expected to boost preventive healthcare spending in these emerging markets.

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

Comments

Popular posts from this blog

Bug Tracking Software Market is Poised to Grow at a Robust Pace by Increasing Adoption of Agile Project Management Trends

Sports and Fitness Apps: Leveraging Technology to Stay Active and Healthy

Laser Projection Market is to Witness High Growth Owing to Advancements in RGB Laser Projection Technology